Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
MediPharm LabsSTU:MLZ -1.09% EV-to-EBITDA is -7.42 as of Aug. 28, 2026. The stock has 4 warning signs investors should review. Among 733 Drug Manufacturers companies, MediPharm Labs ranks worse than 136425.51% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, MediPharm Labs's enterprise value is €15.30 Mil.
MediPharm Labs's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 was €-2.06 Mil. Therefore, MediPharm Labs's EV-to-EBITDA for today is -7.42.
The historical rank and industry rank for MediPharm Labs's EV-to-EBITDA or its related term are showing as below:
STU:MLZ'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -21.51 Med: -1.39 Max: 2463.26
Current: -7.43
During the past 9 years, the highest EV-to-EBITDA of MediPharm Labs was 2463.26. The lowest was -21.51. And the median was -1.39.
STU:MLZ's EV-to-EBITDA is ranked worse than 100% of 733
companies
in the Drug Manufacturers industry
Industry Median: 13.06
vs STU:MLZ: -7.43
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
MediPharm Labs's PE Ratio (TTM) for today is calculated as:
MediPharm Labs's share price for today is €0.0455.
MediPharm Labs's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-0.006.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for MediPharm Labs's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, MediPharm Labs's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
MediPharm Labs EV-to-EBITDA vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, MediPharm Labs's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where MediPharm Labs's EV-to-EBITDA falls into.
MediPharm Labs's current Enterprise Value is €15.30 Mil.
MediPharm Labs's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-2.06 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MediPharm Labs (STU:MLZ) has a EV-to-EBITDA of -7.42 as of Aug. 28, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on MediPharm Labs. According to the industry distribution chart, MediPharm Labs ranks #999999 out of 733 companies in the Drug Manufacturers industry.
Is MediPharm Labs' EV-to-EBITDA too high?
MediPharm Labs' current EV-to-EBITDA is -7.42. Based on the distribution chart, MediPharm Labs ranks #999999 out of 733 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers.
How does MediPharm Labs' EV-to-EBITDA compare to ZTS?
According to the Drug Manufacturers industry distribution chart, MediPharm Labs ranks #999999 out of 733 companies for EV-to-EBITDA. This places MediPharm Labs in the lower half of its industry. The industry median EV-to-EBITDA is 13.06. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Drug Manufacturers company?
The median EV-to-EBITDA among Drug Manufacturers companies is 13.06, based on 733 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on MediPharm Labs. For the Drug Manufacturers industry, the median EV-to-EBITDA is 13.06 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. MediPharm Labs's current EV-to-EBITDA is -7.42. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is MediPharm Labs stock overvalued right now?
Based on GuruFocus' analysis, MediPharm Labs (STU:MLZ) is currently considered Modestly Overvalued. The stock's GF Value™ is €0.04, compared to a current price of €0.05 — trading 13.8% above its estimated fair value. The current EV-to-EBITDA is -7.42. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For MediPharm Labs (STU:MLZ), the current EV-to-EBITDA is -7.42 as of Aug. 28, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
MediPharm Labs Corp and its subsidiaries produce cannabis, purified and pharmaceutical-like cannabis extracts, related derivative products, and cannabis-related medical information and services. Its operating subsidiaries hold cultivation, standard processing, and sale licences under the Cannabis Act (Canada), allowing the cultivation, sale, and distribution of cannabis oil, extracts, edibles, topicals, dried and fresh cannabis, and derivatives to authorized purchasers. Its subsidiary provides clinic services to Canadian patients requiring medical cannabis education and prescriptions. The company operates in one reportable segment, the production and sales of cannabis flower, and generates maximum revenue from Canada, with additional international sales.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:MLZ has been successfully added to your 
